Etin-Osa O Osa1, Keith DeWyngaert1, Daniel Roses2, James Speyer3, Amber Guth2, Deborah Axelrod2, Maria Fenton Kerimian1, Judith D Goldberg4, Silvia C Formenti5. 1. Department of Radiation Oncology, New York University School of Medicine, New York, New York. 2. Department of Surgery, New York University School of Medicine, New York, New York. 3. Department of Medical Oncology, New York University School of Medicine, New York, New York. 4. Department of Population Health, New York University School of Medicine, New York, New York. 5. Department of Radiation Oncology, New York University School of Medicine, New York, New York. Electronic address: Silvia.formenti@nyumc.org.
Abstract
PURPOSE: To report the 5-year results of a technique of prone breast radiation therapy delivered by a regimen of accelerated intensity modulated radiation therapy with a concurrent boost to the tumor bed. METHODS AND MATERIALS: Between 2003 and 2006, 404 patients with stage I-II breast cancer were prospectively enrolled into 2 consecutive protocols, institutional trials 03-30 and 05-181, that used the same regimen of 40.5 Gy/15 fractions delivered to the index breast over 3 weeks, with a concomitant daily boost to the tumor bed of 0.5 Gy (total dose 48 Gy). All patients were treated after segmental mastectomy and had negative margins and nodal assessment. Patients were set up prone: only if lung or heart volumes were in the field was a supine setup attempted and chosen if found to better spare these organs. RESULTS: Ninety-two percent of patients were treated prone, 8% supine. Seventy-two percent had stage I, 28% stage II invasive breast cancer. In-field lung volume ranged from 0 to 228.27 cm(3), mean 19.65 cm(3). In-field heart volume for left breast cancer patients ranged from 0 to 21.24 cm(3), mean 1.59 cm(3). There was no heart in the field for right breast cancer patients. At a median follow-up of 5 years, the 5-year cumulative incidence of isolated ipsilateral breast tumor recurrence was 0.82% (95% confidence interval [CI] 0.65%-1.04%). The 5-year cumulative incidence of regional recurrence was 0.53% (95% CI 0.41%-0.69%), and the 5-year overall cumulative death rate was 1.28% (95% CI 0.48%-3.38%). Eighty-two percent (95% CI 77%-85%) of patients judged their final cosmetic result as excellent/good. CONCLUSIONS: Prone accelerated intensity modulated radiation therapy with a concomitant boost results in excellent local control and optimal sparing of heart and lung, with good cosmesis. Radiation Therapy Oncology Group protocol 1005, a phase 3, multi-institutional, randomized trial is ongoing and is evaluating the equivalence of a similar dose and fractionation approach to standard 6-week radiation therapy with a sequential boost.
PURPOSE: To report the 5-year results of a technique of prone breast radiation therapy delivered by a regimen of accelerated intensity modulated radiation therapy with a concurrent boost to the tumorbed. METHODS AND MATERIALS: Between 2003 and 2006, 404 patients with stage I-II breast cancer were prospectively enrolled into 2 consecutive protocols, institutional trials 03-30 and 05-181, that used the same regimen of 40.5 Gy/15 fractions delivered to the index breast over 3 weeks, with a concomitant daily boost to the tumorbed of 0.5 Gy (total dose 48 Gy). All patients were treated after segmental mastectomy and had negative margins and nodal assessment. Patients were set up prone: only if lung or heart volumes were in the field was a supine setup attempted and chosen if found to better spare these organs. RESULTS: Ninety-two percent of patients were treated prone, 8% supine. Seventy-two percent had stage I, 28% stage II invasive breast cancer. In-field lung volume ranged from 0 to 228.27 cm(3), mean 19.65 cm(3). In-field heart volume for left breast cancerpatients ranged from 0 to 21.24 cm(3), mean 1.59 cm(3). There was no heart in the field for right breast cancerpatients. At a median follow-up of 5 years, the 5-year cumulative incidence of isolated ipsilateral breast tumor recurrence was 0.82% (95% confidence interval [CI] 0.65%-1.04%). The 5-year cumulative incidence of regional recurrence was 0.53% (95% CI 0.41%-0.69%), and the 5-year overall cumulative death rate was 1.28% (95% CI 0.48%-3.38%). Eighty-two percent (95% CI 77%-85%) of patients judged their final cosmetic result as excellent/good. CONCLUSIONS: Prone accelerated intensity modulated radiation therapy with a concomitant boost results in excellent local control and optimal sparing of heart and lung, with good cosmesis. Radiation Therapy Oncology Group protocol 1005, a phase 3, multi-institutional, randomized trial is ongoing and is evaluating the equivalence of a similar dose and fractionation approach to standard 6-week radiation therapy with a sequential boost.
Authors: Kristie Long Foley; Gretchen Kimmick; Fabian Camacho; Edward A Levine; Rajesh Balkrishnan; Roger Anderson Journal: Breast Cancer Res Treat Date: 2006-07-13 Impact factor: 4.872
Authors: Anneke T Schroen; David R Brenin; Maria D Kelly; William A Knaus; Craig L Slingluff Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Benjamin D Smith; Soren M Bentzen; Candace R Correa; Carol A Hahn; Patricia H Hardenbergh; Geoffrey S Ibbott; Beryl McCormick; Julie R McQueen; Lori J Pierce; Simon N Powell; Abram Recht; Alphonse G Taghian; Frank A Vicini; Julia R White; Bruce G Haffty Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-16 Impact factor: 7.038
Authors: Timothy Whelan; Robert MacKenzie; Jim Julian; Mark Levine; Wendy Shelley; Laval Grimard; Barbara Lada; Himu Lukka; Francisco Perera; Anthony Fyles; Ethan Laukkanen; Sunil Gulavita; Veronique Benk; Barbara Szechtman Journal: J Natl Cancer Inst Date: 2002-08-07 Impact factor: 13.506
Authors: Roger T Anderson; Gretchen G Kimmick; Fabian Camacho; J Timothy Whitmire; Carol Dickinson; Edward A Levine; Frank M Torti; Rajesh Balkrishnan Journal: Am J Manag Care Date: 2008-10 Impact factor: 2.229
Authors: J Keith DeWyngaert; Gabor Jozsef; James Mitchell; Barry Rosenstein; Silvia C Formenti Journal: Int J Radiat Oncol Biol Phys Date: 2007-07-15 Impact factor: 7.038
Authors: Cheryl Duzenli; Elisa K Chan; Alanah M Bergman; Sheri Grahame; Joel Singer; Levi Burns; Robert A Olson Journal: BMC Cancer Date: 2022-06-20 Impact factor: 4.638
Authors: Francesco Deodato; Alessio G Morganti; Gabriella Macchia; Savino Cilla; Milly Buwenge; Alice Zamagni; Ilario Ammendolia; Claudio Zamagni; Giovanni P Frezza; Vincenzo Valentini Journal: Breast Cancer (Dove Med Press) Date: 2020-11-12
Authors: Benjamin T Cooper; Xiaochun Li; Samuel M Shin; Aram S Modrek; Howard C Hsu; J K DeWyngaert; Gabor Jozsef; Stella C Lymberis; Judith D Goldberg; Silvia C Formenti Journal: Adv Radiat Oncol Date: 2016-08-09